Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 2.156 Facteur d'impact sur 5 ans: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2017019956
pages 305-319

Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives

Tahir Farooq
Department of Applied Chemistry, Government College University, Faisalabad, Pakistan
Arruje Hameed
Department of Biochemistry, Government College University, Faisalabad, Pakistan
Kanwal Rehman
Institute of Pharmacy, Physiology, and Pharmacology, University of Agriculture, Faisalabad, Pakistan
Muhammad Ibrahim
Department of Applied Chemistry, Government College University Faisalabad, Pakistan
Matloob Ahmed
Department of Chemistry, Government College University, Faisalabad, Pakistan
Tahsin Gulzar
Department of Applied Chemistry, Government College University, Faisalabad, Pakistan
Muhammad Sajid Hamid Akash
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan

RÉSUMÉ

Hepatitis C virus (HCV) presents a serious global health threat. Initially, the health-care community mainly focused on interferon (IFN)-based therapeutic options to eradicate HCV, but with the passage of time, these applications became unsuitable due to some serious side effects related to the use of IFN. In recent years, research conducted on different phases of HCV's life cycle has opened a new gateway for the use of a direct-acting new generation of anti-HCV agents. Their safer and ultrarapid response has made possible the introduction of triple therapy and use of IFN-free therapeutic treatment strategies. However, the high cost of these successful therapies has raised serious concerns, particularly in low-income countries, and this has forced pharmaceutical scientists to explore more cost-effective IFN-free alternatives for the treatment of HCV. In this article, we have briefly summarized the latest data regarding the research and development of non-IFN-based antiviral agents. The studies mentioned in this article highlight the significance of non-IFN-based direct-acting antiviral (DAA) agents. Economical alternative anti-HCV agents are expected to become available in the near future for better and more cost-effective treatments of HCV.


Articles with similar content:

Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 4
Tahir Farooq, Muhammad Ibrahim, Muhammad Imran Qadir, Muhammad Sajid Hamid Akash, Kanwal Rehman, Arruje Hameed
Options and Opportunities for Clinical Management and Treatment of Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Udita Agrawal, Devyani Dube, Madhu Gupta, Suresh P. Vyas
Current Developments in Therapeutic Drug Targeting for the Management of Rheumatoid Arthritis: An Emerging Paradigm
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 6
T. M. Pramod Kumar, Madhugiri Prakash Venkatesh, Deeksha R. Pai
Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Crystal L. Mackall, Rimas J. Orentas
Immune Responses Against Persistent Viral Infections: Possible Avenues for Immunotherapeutic Interventions
Critical Reviews™ in Immunology, Vol.28, 2008, issue 2
Edward J. Usherwood, Michael J. Molloy, Shinichiro Fuse